0001209191-12-002549.txt : 20120106 0001209191-12-002549.hdr.sgml : 20120106 20120106161246 ACCESSION NUMBER: 0001209191-12-002549 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120104 FILED AS OF DATE: 20120106 DATE AS OF CHANGE: 20120106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: REYNOLDS FRANCIS CENTRAL INDEX KEY: 0001503383 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-52089 FILM NUMBER: 12514752 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INVIVO THERAPEUTICS HOLDINGS CORP. CENTRAL INDEX KEY: 0001292519 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 475-1520 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Design Source, Inc. DATE OF NAME CHANGE: 20040602 4 1 c26597_4x0.xml MAIN DOCUMENT DESCRIPTION X0304 4 2012-01-04 0001292519 INVIVO THERAPEUTICS HOLDINGS CORP. NVIV 0001503383 REYNOLDS FRANCIS C/O INVIVO THERAPEUTICS HOLDINGS CORP. ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 1 1 1 0 CEO, CFO COMMON STOCK, $0.00001 PAR VALUE 2012-01-04 4 S 0 44497 2.6247 D 14853163 D COMMON STOCK, $0.00001 PAR VALUE 2012-01-05 4 S 0 109000 2.6310 D 14744163 D COMMON STOCK, $0.00001 PAR VALUE 2012-01-06 4 S 0 96503 2.5323 D 14647660 D COMMON STOCK, $0.00001 PAR VALUE 13603 I By 401(k) Plan The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The reporting person undertakes to provide InVivo Therapeutics Holdings Corp. ("InVivo"), any security holder of InVivo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 2 and 3 of this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.7035, inclusive. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60, inclusive. Between October 1 and December 31, 2011, the reporting person acquired 13,603 shares of InVivo Therapeutics Holdings Corp. common stock under a 401(k) plan. The information in this report is based on a plan statement dated as of December 31, 2011. /S/ ELIZABETH FRASER, AS ATTORNEY IN FACT 2012-01-06